Novel chemotherapeutic approaches to brain tumors

Hematology/Oncology Clinics of North America

Volumn 15, Issue 6, 2001, Pages 1027-1052

  Dropcho, Edward J ^a,b  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; HYDROXYUREA; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; MITOLACTOL; PACLITAXEL; PREDNISONE; PROCARBAZINE; TEMOZOLOMIDE; TIOGUANINE; TOPOTECAN; VINCRISTINE;

ASTROCYTOMA; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; GLIOBLASTOMA; HUMAN; MEDULLOBLASTOMA; MENINGIOMA; OLIGODENDROGLIOMA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 0035209004     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70266-5     Document Type: Article

References (159)

1. Long-term survival in primary CNS lymphoma
2. High dose chemotherapy with autologous stem cell rescue in adults with malignant primary brain tumors
3. Treatment for primary CNS lymphoma: The next step
4. Leptomeningeal tumor in primary central nervous system lymphoma: Recognition, significance, and implications
5. Primary intracerebral malignant lymphoma: Report of 248 cases
6. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine
7. Antiangiogenic therapy in brain tumor models
8. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization
9. The C5R protocol: A regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression
10. High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series
11. Cisplatin and BCNU chemotherapy for anaplastic oligodendrogliomas
12. Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy
13. Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma
14. A phase II trial of primary chemotherapy with temozolomide in patients with low-grade cerebral gliomas
15. Procarbazine and high-dose tamoxifen as a second line regimen in recurrent high-grade gliomas: A phase II study
16. Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme
17. Phase II trial with BCNU plus alphainterferon in patients with recurrent high-grade gliomas
18. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas
19. A phase II trial of irinotecan in recurrent glioma
20. Phase II evaluation of infusional etoposide and cisplatin in patients with recurrent astrocytoma
21. Chemotherapy for anaplastic oligodendroglioma
22. Myeloablative chemotherapy for recurrent aggressive oligodendroghoma
23. Molecular diagnosis of anaplastic oligodendroglioma subtype
24. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
25. Multivariate analysis of prognostic factors in adult patients with medulloblastoma: Retrospective study of 156 patients
26. Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor
27. Long survival in patients with acquired immune deficiency syndrome-related primary central nervous system lymphoma
28. Adjuvant combined modality therapy for malignant meningiomas
29. Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas
30. Adult medulloblastoma: Prognostic factors and patterns of relapse
31. Temozolomide for patients with recurrent glioma
32. A phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants
33. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy
34. Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy
35. Topotecan as salvage therapy for refractory or relapsed primary central nervous system lymphoma
36. Intra-arterial carboplatin chemotherapy for brain tumors: A dose escalation study based on cerebral blood flow
37. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen
38. Primary CNS lymphoma: Treatment with combined chemotherapy and radiotherapy
39. Malignant glioma: Who benefits from adjuvant chemotherapy?
40. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA
41. Interferon-alpha 2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma
42. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors
43. Pre-radiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas
44. Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas
45. The prognostic impact of prior low grade histology in patients with anaplastic gliomas: A case-control study
46. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma
47. The treatment of medulloblastoma: Results of a prospectively randomized trial of radiation therapy with and without CCNU, vincristine and prednisone
48. High-dose BCNU and autologous progenitor cell transplantation given with intra-arterial cisplatin and simultaneous radiotherapy in the treatment of high-grade gliomas: Benefit for selected patients
49. Preirradiation paclitaxel in glioblastoma multiforme: Efficacy, pharmacology, and drug interactions
50. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
51. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
52. Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS
53. Oligodendroglioma: An appraisal of recent data pertaining to diagnosis and treatment
54. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients
55. Temozolomide and treatment of malignant glioma
56. Topotecan treatment of adults with primary malignant glioma
57. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma
58. Irinotecan therapy in adults with recurrent or progressive malignant glioma
59. Phase II study of prolonged oral therapy with etoposide for patients with recurrent malignant glioma
60. Chemotherapy of medulloblastoma
61. Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results
62. High dose chemotherapy with autologous stem-cell rescue for adult patients with recurrent medulloblastoma
63. Preradiation treatment of newly diagnosed anaplastic astrocytomas and glioblastoma multiforme using temozolomide
64. Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation for adults with astrocytomas
65. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long-term outcome
66. Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD)
67. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas
68. Age influences chemotherapy response in astrocytomas
69. Chemotherapy response criteria in malignant glioma
70. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma
71. Adult medulloblastoma: Multiagent chemotherapy
72. Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma
73. Phase III study comparing three cycles of infusional BCNU/cisplatin followed by radiation with radiation and concurrent BCNU for patients with newly diagnosed supratentorial glioblastoma multiforme
74. Cisplatin does not enhance the effect of radiation therapy in malignant gliomas
75. Cis-retinoic acid for the treatment of recurrent glioblastoma multiforme
76. A phase II study of temozolomide plus marimastat for recurrent glioblastoma multiforme
77. Carboplatin chemotherapy before irradiation in newly diagnosed glioblastoma multiforme
78. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone
79. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: Response to therapy and quality of life of patients
80. Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: Patient series and literature review
81. A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain
82. Intratumoral DTI-015 for inoperable recurrent malignant gliomas
83. PCV salvage chemotherapy for recurrent primary CNS lymphoma
84. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas
85. Intra-arterial mannitol infusion in the chemotherapy for malignant brain tumors
86. Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS
87. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with BCNU
88. Salvage therapy with etoposide and carboplatin for late stage recurrent malignant gliomas
89. Phase II evaluation of temozolomide and cis-retinoic acid for the treatment of recurrent and progressive malignant gliomas
90. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: A phase II study
91. Combined treatment modality for anaplastic oligodendroglioma: A phase II study
92. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B
93. PCV chemotherapy for recurrent glioblastoma multiforme
94. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligodendrogliomas
95. Pre-radiation chemotherapy for malignant glioma in adults
96. Randomized comparison of intra-arterial versus intravenous infusion of ACNU for newly diagnosed patients with glioblastoma
97. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: Results of the German prospective randomized trial HIT '91
98. Carboplatin and cis-retinoic acid for recurrent glioblastoma multiforme
99. Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas
100. Preliminary results of a phase I clinical trial of adenovirus-mediated p53 gene therapy for recurrent glioma
101. A phase 1-2 trial of superselective carboplatin, low-dose infusional 5-fluorouracil and concurrent radiation for high-grade gliomas
102. Tumor regression with regional distribution of the targeted toxin TF-CRM 107 in patients with malignant brain tumors
103. Supratentorial low-grade glioma in adults: An analysis of prognostic factors and timing of radiation
104. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV for the treatment of anaplastic gliomas
105. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme
106. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report
107. High-dose BCNU with ABMT followed by radiation therapy in the treatment of supratentorial glioblastoma multiforme
108. Therapy for patients with high grade astrocytoma using intraarterial chemotherapy and radiation therapy
109. Phase II study of thalidomide as an antiangiogenic agent in the treatment of recurrent glioblastoma multiforme
110. Low-grade oligodendroglioma responds to chemotherapy
111. Tamoxifen and carboplatin combinational treatment of high-grade gliomas
112. Cognitive outcomes and longterm follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma
113. Combined modality approach to treatment of malignant gliomas: Re-evaluation of RTOG 7401/ECOG 1374 with longterm follow-up
114. High-dose methotrexate for primary CNS lymphoma in the elderly
115. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma
116. Primary central nervous system non-Hodgkin's lymphoma: Survival advantages with combined initial therapy? A final report of the North Central Cancer Treatment Group study 86-72-52
117. Long-term outcome of low-grade oligodendroglioma and mixed glioma
118. Medulloblastoma: Clinical and biologic aspects
119. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group study
120. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy
121. Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma
122. Long-term prognosis for atypical and malignant meningiomas: A study of 71 surgical cases
123. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: A pilot study in humans
124. A phase I study of high-dose BCNU, etoposide, and escalating-dose thiotepa with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors
125. Malignancy in meningiomas: A clinicopathologic study of 116 patients, with grading implications
126. Meningioma grading: An analysis of histologic parameters
127. High dose chemotherapy for the treatment of malignant brain tumors
128. Salvage chemotherapy for oligodendroglioma
129. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors
130. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective reivew of Radiation Therapy Oncology Group protocols comparing survival with carmustine or PCV adjuvant chemotherapy
131. A phase II study of BCNU and temozolomide for recurrent glioblastoma multiforme
132. Phase II trial of BCNU plus O6-benzylguanine for patients with recurrent or progressive malignant glioma
133. A phase III clinical evaluation of herpes simplex virus type I thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme
134. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
135. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: Results of a critical review of the literature
136. Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: A phase II study
137. Hydroxyurea for treatment of unresectable and recurrent meningiomas
138. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: Initial report of Radiation Therapy Oncology Group protocol 88-06
139. Validation and predictive power of Radiation Therapy Oncology Group recursive partitioning analysis classes for malignant glioma patients
140. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir
141. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma
142. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas
143. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas
144. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma
145. Morbidity and survival after BCNU wafer implantation for recurrent glioblastoma: A retrospective case-matched cohort series
146. Adjuvant chemotherapy for medulloblastoma: The first multicentre controlled trial of the International Society of Paediatric Oncology (SIOP)
147. Primary intracerebral malignant lymphoma: A clinicopathological study of 89 patients
148. Temozolomide chemotherapy in recurrent oligodendrogliom
149. Temozolomide chemotherapy in recurrent oligodendroglioma
150. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy
151. A phase II study of intravenous carboplatin for the treatment of recurrent gliomas
152. Placebo controlled multicenter double-blind randomized prosepctive phase III trial of local chemotherapy with biodegradable carmustine implants (Gliadel) in 240 patients with malignant gliomas: Final results
153. Outcomes and prognostic factors in recurrent glioma patients treated enrolled onto phase II clinical trials
154. A phase II study of temozolomide vs. Procarbazine in patients with glioblastoma multiforme at first relapse
155. A combination of temozolomide and interferon-A in recurrent malignant gliomas: A phase II study
156. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid
157. Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: A phase I/II study
158. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse
159. Metastasis, stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: Conclusions from the Children's Cancer Group 921 randomized phase III study